Alentis recently closed CHF 60 M Series B financing round (USD 67 million) led by Morningside Venture Investments and joined by Jeito Capital and the Series A investors to accelerate its lead programs for fibrosis and fibrosis-driven cancers into clinical development, and to expand the wider potential of targeting CLDN1 in other fibrotic diseases.

Alentis was founded in 2019 with CHF12.5 M Series A financing co-led by Swiss venture capital firms BioMed Partners and BB Pureos Bioventures, with additional investments from Bpifrance, Schroder Adveq and the German High-Tech Gründerfonds.